RP Bio Inc. (KOSDAQ:314140)
5,980.00
-90.00 (-1.48%)
At close: Sep 11, 2026
RP Bio Revenue
RP Bio had revenue of 39.77B KRW in the quarter ending June 30, 2026, with 11.40% growth. This brings the company's revenue in the last twelve months to 141.42B, up 9.55% year-over-year. In the year 2025, RP Bio had annual revenue of 136.22B with 9.88% growth.
Revenue (ttm)
141.42B
Revenue Growth
+9.55%
P/S Ratio
0.37
Revenue / Employee
n/a
Employees
n/a
Market Cap
51.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 136.22B | 12.25B | 9.88% |
| Dec 31, 2024 | 123.97B | -27.08B | -17.93% |
| Dec 31, 2023 | 151.05B | 12.94B | 9.37% |
| Dec 31, 2022 | 138.11B | 23.15B | 20.13% |
| Dec 31, 2021 | 114.96B | 17.04B | 17.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jin Yang Pharmaceutical | 124.61B |
| Sinsin Pharmaceutical | 123.05B |
| Hwail Pharmaceutical | 107.87B |
| GeneBioTech Co. ,Ltd | 89.31B |
| Sinil Pharmaceutical | 86.82B |
| Kyung Nam Pharm | 54.89B |
| Eagle Veterinary Technology Co.,Ltd | 44.73B |
| Optipharm.CO.,LTD | 23.59B |